Ratio Therapeutics CEO Jack Hoppin (L) and president and CSO John Babich

Ra­tio rais­es $50M as ra­dio­phar­ma field finds its groove

Ra­dio­phar­ma­ceu­ti­cal biotech Ra­tio Ther­a­peu­tics has raised a $50 mil­lion Se­ries B to bring its first ther­a­peu­tic in­to the clin­ic, it said Wednes­day morn­ing.

The biotech has now raised a to­tal of $90 mil­lion since its found­ing in mid-2021. Based in Boston’s Sea­port Dis­trict, the biotech un­veiled it­self in June 2022 and has al­ready inked col­lab­o­ra­tions with Bay­er, Mer­ck and Lan­theus.

Ra­dio­phar­ma com­pa­nies have been in the news with con­sid­er­ably more fre­quen­cy in re­cent months with two key ac­qui­si­tions by Eli Lil­ly and Bris­tol My­ers Squibb, and fi­nanc­ing rounds rolling in for a string of star­tups, like Art­bio, Con­ver­gent Ther­a­peu­tics and Ab­dera Ther­a­peu­tics. Bris­tol My­ers in­vest­ed in Ra­tio’s Se­ries B. The ex­pand­ing mar­ket is al­so caus­ing CD­MOs to iron out sup­ply chain bumps and con­fig­ure ac­cess to raw ma­te­ri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.